Photo from wikipedia
Hypercoagulability and endothelial dysfunction are hallmarks of coronavirus disease 2019 (COVID‐19) and appear to predict disease severity. A high incidence of thrombosis despite thromboprophylaxis is reported in patients with moderate… Click to show full abstract
Hypercoagulability and endothelial dysfunction are hallmarks of coronavirus disease 2019 (COVID‐19) and appear to predict disease severity. A high incidence of thrombosis despite thromboprophylaxis is reported in patients with moderate to severe COVID‐19. Recent randomized clinical trials suggest that therapeutic‐intensity heparin confers a survival benefit in moderate‐severity COVID‐19 compared to standard‐intensity heparin, potentially by harnessing heparin‐mediated endothelial‐stabilizing and anti‐inflammatory effects.
Journal Title: Journal of Thrombosis and Haemostasis
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!